GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Imugene IMU.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.04

+5.56%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Imugene — daily ASX:IMU

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Imugene on TradingView ↗
Market value
A$8.3m
Last close × shares
Volume
1.7m
Shares, 9 Nov 2026

About Imugene

Its shares trade on ASX under the ticker IMU.AX. It has been listed since 2 December 1993. In the fiscal year to 30 June 2025, it reported revenue of A$4.4m and a net loss of A$69.0m. At that date it held total assets of A$83.6m and shareholders' equity of A$45.0m.

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The firm is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The firm is also engaged in the research, development and commercialization of health technologies. HER-Vaxx is a cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has completed a Phase I clinical trial with over 10 HER-2 positive patients with metastatic breast cancer. The company was shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu. HER-Vaxx has stimulated the production of HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. The firm is also developing mimotope-based immunotherapies against validated and oncology targets.

Figures and description from our data supplier, not checked against the company's own report.

More about Imugene →

Latest on Imugene

Our reporting

We have not reported on Imugene yet.

Next results

3 Mar 2027

Due on 3 Mar 2027. Analysts expect earnings of -0.03 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Imugene's ticker?

Imugene trades as IMU.AX on ASX, under ISIN AU000000IMU9.

What was Imugene's last closing price?

0.04 on 9 Nov 2026. The figure is in AUD and is never converted.

When does Imugene next report results?

Results are expected on 3 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.